THE ARISING · Longevity & Healthspan
Review Links Gut Bacteria to Parkinson's Inflammation and Levodopa Availability
Constipation that shows up a decade or more before tremor or stiffness may be an early clue to Parkinson's disease in some people, and gut bacteria may also change how the main Parkinson's drug behaves in the body, according to a new review in Frontiers in Immunology.
The paper, published Nov. 10 by researchers at Nova Southeastern University and other institutions, is a review. It gathers existing evidence from mouse experiments, human cohort studies and early trials rather than reporting new data. Parkinson's affects more than 10 million people worldwide, the authors write.
The central idea is a "gut-first" form of the disease. In a subset of patients, the authors write, the misfolded protein α-synuclein may begin to build up in the nerves of the gut and then travel to the brain. In transgenic mice, α-synuclein overproduction in gut nerves led to clumps there, spread to the brainstem along the vagus nerve, and caused slowed gut movement. In another mouse study the review describes, injecting α-synuclein fibrils into the duodenum led to spread toward the substantia nigra, the brain region that loses dopamine-producing cells in Parkinson's. Cutting the vagus nerve blocked that spread.
The gut-first account remains a proposed subtype model; the review notes that human autopsy findings neither establish nor exclude it.
A human association study provides indirect support, but does not establish gut-to-brain causation. In a prospective cohort followed for 24 years, fewer than one bowel movement a day was linked to a 4.1 to 4.5 times higher risk of Parkinson's, with an average of about 12 years between constipation and the start of movement symptoms. The authors also name REM sleep behavior disorder and cardiac sympathetic denervation as signs that may mark the gut-first subtype.
The review lays out how gut bacteria may feed brain inflammation. In dysbiosis, an imbalanced gut community, bacteria that make short-chain fatty acids decline, bacteria that make lipopolysaccharide increase, and the gut barrier weakens. According to the authors, this activates a signaling pathway called TLR4/NF-κB, primes microglia (the brain's immune cells) toward a disease-linked state, and promotes α-synuclein misfolding. They add that the complement system, part of the immune response, links gut bacteria to nerve damage.
Medication is the second theme. The authors report that gut bacteria influence how levodopa moves through the body via bacterial tyrosine decarboxylase activity. The microbiome also interacts with COMT inhibitors, drugs often used alongside levodopa, and alters how much drug becomes available.
The review also covers possible markers for diagnosis. These include the ratio of trimethylamine N-oxide to butyrate, secondary bile acids, phosphorylated α-synuclein in skin, and seeding amplification assays, which detect misfolded protein. The authors cite epidemiological evidence linking earlier antibiotic exposure and inflammatory bowel disease to Parkinson's risk.
Treatments aimed at the gut are in early testing. The review covers short-chain fatty acid supplements, fecal microbiota transplantation, GLP-1 receptor agonists and targeted probiotics. According to the authors, microbiome-directed approaches may help most in the gut-first subtype, which is why they call for trials that sort patients by subtype.
Next to watch: trials that enroll patients by gut-first features such as prodromal constipation or REM sleep behavior disorder, which will show whether microbiome-directed therapies work in the people the theory predicts.